Graham Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Graham Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-34,153	Closed	-$219K	–	1226
2025 Q2	$219K	Buy	+34,153	New	+$166K	﹤0.01%	1098
2024 Q4	–	Sell	-67,956	Closed	-$220K	–	1216
2024 Q3	$220K	Sell	67,956 -253,911	-79%	-$571K	﹤0.01%	885
2024 Q2	$612K	Sell	321,867 -202,760	-39%	-$393K	0.01%	522
2024 Q1	$1.49M	Buy	+524,627	New	+$6.86M	0.03%	308
2023 Q4	–	Sell	-56,241	Closed	-$1.03M	–	983
2023 Q3	$1.03M	Buy	56,241 +25,689	+84%	+$543K	0.02%	360
2023 Q2	$659K	Buy	+30,552	New	+$825K	0.02%	484

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Graham Capital Management's AMLX Position: Q3 2025 in Review

Graham Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 34,153 shares — an estimated $219K sold.

Graham Capital Management first reported a position in AMLX in Q2 2023 and held it in 6 quarters. The position peaked at $1.49M in Q1 2024. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

Graham Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Graham Capital Management sold 34,153 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $219K.
Graham Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Graham Capital Management's Amylyx Pharmaceuticals position peaked at $1.49M in Q1 2024.
169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.